Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:IMRX

Immuneering Q1 2026 Earnings Report

Immuneering logo
$4.27 -0.30 (-6.56%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$4.34 +0.07 (+1.52%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immuneering EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Announcement Details

Quarter
Q1 2026
Date
5/15/2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:30AM ET

Upcoming Earnings

Immuneering's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immuneering's Q1 2026 Press ReleasePress Release
(8-K)
Immuneering's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Immuneering Earnings Headlines

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 11 at 7:36 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/immuneering-to-present-at-the-aacr-conference-on-pancreatic-cancer-highlighting-atebimetinib-s-dual-mechanism-for-extended-survival-1036535607
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 11 at 7:36 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/immuneering-to-present-at-the-aacr-conference-on-pancreatic-cancer-highlighting-atebimetinib-s-dual-mechanism-for-extended-survival-1036535607
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
September 13 at 1:00 AM  |  Stansberry Research (Ad)
Immuneering to Present Data on Atebimetinib’s Tumor-Reducing and Body Mass-Preserving Effects in Pancreatic Cancer at AACR Conference
September 10 at 7:51 AM  |  quiverquant.comQ
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
September 10 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359390/0/en/immuneering-to-present-at-the-aacr-conference-on-pancreatic-cancer-highlighting-atebimetinib-s-dual-mechanism-for-extended-survival.html
Immuneering to Participate in Upcoming Investor Conferences
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3356257/0/en/immuneering-to-participate-in-upcoming-investor-conferences.html
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

View Immuneering Profile
Earnings Tools